AU2013357283A1 - Medicament for atrophy treatment or increasing cell growth - Google Patents

Medicament for atrophy treatment or increasing cell growth Download PDF

Info

Publication number
AU2013357283A1
AU2013357283A1 AU2013357283A AU2013357283A AU2013357283A1 AU 2013357283 A1 AU2013357283 A1 AU 2013357283A1 AU 2013357283 A AU2013357283 A AU 2013357283A AU 2013357283 A AU2013357283 A AU 2013357283A AU 2013357283 A1 AU2013357283 A1 AU 2013357283A1
Authority
AU
Australia
Prior art keywords
cells
serf2
cell
muscle
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013357283A
Other languages
English (en)
Inventor
Rudolf Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIMU TRADE CONSULTING & Co LEASING KG GmbH
Original Assignee
SIMU TRADE CONSULTING & CO LEASING KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIMU TRADE CONSULTING & CO LEASING KG GmbH filed Critical SIMU TRADE CONSULTING & CO LEASING KG GmbH
Publication of AU2013357283A1 publication Critical patent/AU2013357283A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013357283A 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth Abandoned AU2013357283A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197192.3A EP2742935A1 (en) 2012-12-14 2012-12-14 SERF2 for the treatment of atrophy and for increasing cell growth
EP12197192.3 2012-12-14
PCT/EP2013/076547 WO2014090991A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Publications (1)

Publication Number Publication Date
AU2013357283A1 true AU2013357283A1 (en) 2015-07-09

Family

ID=47355920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013357283A Abandoned AU2013357283A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Country Status (7)

Country Link
US (2) US9637529B2 (https=)
EP (2) EP2742935A1 (https=)
JP (1) JP2016508123A (https=)
CN (1) CN105163726A (https=)
AU (1) AU2013357283A1 (https=)
CA (1) CA2895131A1 (https=)
WO (1) WO2014090991A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
JP2020502078A (ja) * 2016-11-30 2020-01-23 パイアン・バイオテクノロジー・インコーポレイテッドＰａｅａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｉｎｃ． ミトコンドリアを含む医薬組成物
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN113337460A (zh) * 2021-06-10 2021-09-03 呼和浩特职业学院 一种绵羊骨骼肌卫星细胞的高效分离和纯化方法
CN118108828B (zh) * 2022-11-29 2025-10-28 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
CN117538545B (zh) * 2024-01-09 2024-07-05 上海众启生物科技有限公司 一种用于阿尔茨海默症检测的蛋白抗原组合及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399776A1 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
US20170253641A1 (en) 2017-09-07
EP2931264A1 (en) 2015-10-21
JP2016508123A (ja) 2016-03-17
CA2895131A1 (en) 2014-06-19
CN105163726A (zh) 2015-12-16
US9637529B2 (en) 2017-05-02
WO2014090991A1 (en) 2014-06-19
US20150307568A1 (en) 2015-10-29
EP2742935A1 (en) 2014-06-18

Similar Documents

Publication Publication Date Title
AU2013357283A1 (en) Medicament for atrophy treatment or increasing cell growth
Li et al. Dental pulp stem cell‐derived exosomes alleviate cerebral ischaemia‐reperfusion injury through suppressing inflammatory response
Hsieh et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Jørgensen et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo
Gorham et al. The expression of the neuronal intermediate filament protein peripherin in the rat embryo
Kim et al. Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage
Bénard et al. Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum
Chen et al. CKLF1 aggravates focal cerebral ischemia injury at early stage partly by modulating microglia/macrophage toward M1 polarization through CCR4
AU2012390200B2 (en) Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
EP1766768B1 (en) Use of lacritin in promoting ocular cell survival
Lee et al. Involvement of BDNF/ERK signaling in spontaneous recovery from trimethyltin-induced hippocampal neurotoxicity in mice
Binamé et al. Disruption of Sema3A/Plexin‐A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination
Zhang et al. Reducing host aldose reductase activity promotes neuronal differentiation of transplanted neural stem cells at spinal cord injury sites and facilitates locomotion recovery
Olianas et al. Inhibition of TNF-α-induced neuronal apoptosis by antidepressants acting through the lysophosphatidic acid receptor LPA1
Ji et al. Human Umbilical Cord Mesenchymal Stem Cells Attenuate Ocular Hypertension‐Induced Retinal Neuroinflammation via Toll‐Like Receptor 4 Pathway
Barbon et al. In vitro assessment of TAT—Ciliary Neurotrophic Factor therapeutic potential for peripheral nerve regeneration
Cancedda et al. Ex-FABP: a fatty acid binding lipocalin developmentally regulated in chicken endochondral bone formation and myogenesis
CN106148276A (zh) 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
Estudillo et al. Gas1 is present in germinal niches of developing dentate gyrus and cortex
Aronica et al. Expression and regulation of voltage-gated sodium channel β1 subunit protein in human gliosis-associated pathologies
Hösli et al. Expression of GABAA receptors by reactive astrocytes in explant and primary cultures of rat CNS
Trofimova Molecular mechanisms of retina pathology and ways of its correction
Xu et al. Increased expression of BAG-1 in rat brain cortex after traumatic brain injury
Chung et al. TGF-β-stimulated aberrant expression of class III β-tubulin via the ERK signaling pathway in cultured retinal pigment epithelial cells
JP6397122B2 (ja) 血管新生関連疾患を治療するためのペプチドの使用

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application